• JW Pharmaceutical’s board on Sept. 29, 2026 decided to acquire all shares of Solidus Investment to accelerate open innovation.
• Deal calls for buying 2,000,000 shares for KRW 30.728 billion in cash, equal to 8.32% of equity.
• Transaction would lift ownership to 100% of Solidus Investment.
• Acquisition is scheduled for Sept. 29, 2026; other procedural matters were also addressed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JW Pharmaceutical Corporation published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260929800726), on September 29, 2026, and is solely responsible for the information contained therein.